Oral magnesium supplements for cancer treatment-induced hypomagnesemia: Results from a pilot randomized trial.

ABSTRACT:

Background and aims

Optimal management of cancer treatment-induced hypomagnesemia (hMg) is not known. We assessed the feasibility of using a novel pragmatic clinical trials model to compare two commonly used oral Mg replacement strategies.

Methods

Patients with grade 1 to 3 hMg while receiving either platinum-based chemotherapy or epidermal growth factor receptor inhibitors (EGFRI) were randomized to oral magnesium oxide (MgOx) or oral magnesium citrate (MgCit). The trial methodology utilized the integrated consent model. Feasibility would be successful if; accrual rate was ≥5 patients a month and if measures of patient and physician engagement, were > 50%. Secondary endpoints included; comparison of Mg levels, cardiac arrhythmias, and rates of treatment delay/hospitalizatio

SUBMITTER: Awan A 

PROVIDER: S-EPMC8669698 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature